Company: EDSA
Filing Date: 2025-08-08
Form Type: 10-Q
Source: 0001171843-25-005236
Chunk: 27

Company: Edesa Biotech, Inc.
Filing Date: 2025-08-08
Form: 10-Q
Item: Part I, Item 8
Chunk 27
---
 Ended June 30, 2025 and 2024

Total operating expenses for each of the three months ended June 30, 2025 and June 30, 2024 were $1.9 million.

			●

			The following table summarizes our R&D expenses incurred during the three months ended June 30, 2025 and 2024, together with the dollar increase or decrease in those items:

			Three Months Ended June 30, 2025

			Change

			June 30, 2025

			June 30, 2024

			$ 

			Program-specific external costs:

			EB06

			$
			226,118

			$
			-

			$
			226,118

			EB05

			396,993

			640,030

			(243,037
			)

			Other development and discovery programs

			40,370

			22,866

			17,504

			Total program-specific costs

			663,481

			662,896

			585

			Unallocated internal costs

			Non-program specific external costs

			-

			1,762

			(1,762
			)

			Unallocated internal costs

			275,586

			232,647

			42,939

			Total unallocated internal costs

			275,586

			234,409

			41,177

			Total research and development costs

			939,067

			897,305

			41,762

			●

			Research and development (R&D) expenses were $0.9 million for each of the three months ended June 30, 2025 and June 30, 2024, as an increase in EB06-related expenses associated with preparations for the Phase 2 clinical study was offset by a decrease in external research expenses related to EB05. Our R&D expenses consist primarily of employee-related expenses, including salaries, benefits, taxes, travel, and share-based compensation expense for personnel in R&D functions; expenses related to process development and production of product candidates paid to contract manufacturing organizations, including the cost of acquiring, developing, and manufacturing research material; costs associated with clinical activities, including expenses for contract research organizations; and clinical